KeyBanc raises Encompass Health stock price target on strong earnings
KeyBanc raised its price target for Encompass Health (NYSE:EHC) to $150 from $147, citing strong Q3 results. Core EBITDA beat estimates by 10% with 23% YoY growth, driven by acuity improvements and expense management. The company reported $1.52B EBITDA over the last 12 months. Same-store volumes grew 3.0%, with expectations of further improvement. Management is optimistic about 2027 and RCD expansion. The stock has returned 32% over six months, trading near its 52-week high of $133.75.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance underpin KeyBanc's target increase, suggesting continued demand for inpatient rehabilitation services.
Market read
EHC's strong earnings and upgraded target may drive short‑term buying interest and lift related healthcare stocks.
What to watch
Potential headwinds from payer reimbursement pressure and upcoming regulatory changes in rehab services.
Background
Encompass Health reported Q3 2026 core EBITDA of $1.52 bn, a 10% beat, and adjusted EPS of $1.52 versus $1.36 consensus.
Ticker impact
KeyBanc raised its price target on Encompass Health (EHC) to $150 after the company posted Q3 results that beat EBITDA expectations.
likely upward pressure as investors price in the higher target and strong earnings beat.
The price target increase and overweight rating directly follow a earnings beat, providing a clear catalyst for near‑term buying.
Market effects
Strong rehab earnings may lift other healthcare providers and REITs focused on inpatient services.
U.S. healthcare sector gains modestly in early trading.
Limited to U.S. markets; no immediate global ripple.
Counterpoint
If the earnings beat is already priced in, the target raise may be overstated and could lead to short‑term profit taking.
Key entities
- companyEncompass Health Corp
U.S. healthcare provider specializing in inpatient rehabilitation.
- analystKeyBanc Capital Markets
Investment bank that raised the price target.
